General
Preferred name
WM 1119
Synonyms
WM1119 ()
WM-1119 ()
Compound-4 ()
P&D ID
PD087787
CAS
2055397-28-7
Tags
available
free of charge
probe
Probe info
Probe type
experimental probe
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
COMMENT This probe has been developed by a strong medicinal chemistry approach for which more than 180 analogs have been profiled in in vitro KAT6A activity assays (Priebbenow J Med Chem 2020). WM-1119 is a highly potent KAT6A inhibitor with high selectivity over KAT5 and KAT7. A crystal structure confirms the binding mode as an acetyl-CoA competitive inhibitor. No detailed SAR data compared to KAT6B have been reported, but the authors state that limited testing suggests these compounds behaves as dual KAT6A/B inhibitor. The compound has further been profiled against a panel of 159 targets where no other affinities have been detected. However, no general methods like interaction proteomics or thermal proteome profiling for comprehensively identifying interactors have been identified. Considering that the compound acts as a competitive inhibitor of acetyl-CoA, it will be important to profile whether other acetyl-CoA binders are also interacting with WM-1119. Cellular data reported for this compound rely on the measurement of indirect effects like growth inhibition and expression changes, whereas direct measurement of acetylation changes has only been reported for the analog WM-8014. Detailed characterization of physicochemical and pharmacological parameters including solubility, plasma protein binding, microsome stability and permeability and plasma concentrations after IV and oral dosing in rat and IP dosing in mice are available. Aug 28 2020 - 8:03am; I agree with the recommended oral dose in rats, however I do not recommend dosing rats intravenously with WM-1119. In mice, I recommend dosing intraperitoneally at 50mg/kg Sep 24 2020 - 11:42am
DESCRIPTION WM-1119 is a highly potent and selective KAT6A inhibitor, with an IC50 of 0.25 ¦ÌM for KAT6A in lymphoma cells, the binding KD values of WM-1119 with KAT6A, KAT5 and KAT7 are 2 nM, 2.2 ¦ÌM, 0.5 ¦ÌM , respectively[1].
PRICE 56
MOA Inhibitor (Chemical Probes.org)
DESCRIPTION WM-1119 is a highly potent, selective inhibitor of lysine acetyltransferase KAT6A with IC50 of 0.25 μM. It is 1,100-fold and 250-fold more active against KAT6A than against KAT5 or KAT7, respectively. (BOC Sciences Bioactive Compounds)
DESCRIPTION WM-1119 is a highly potent, selective KAT6A/B inhibitor (TargetMol Bioactive Compound Library)
DESCRIPTION Potent and selective KAT6A and KAT6B inhibitor (Tocris Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
15
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
Chemical Probes.org
CZ-OPENSCREEN Bioactive Library
Enamine BioReference Compounds
EUbOPEN Chemogenomics Library
High-quality chemical probes
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
Open Science Probes
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
External IDs
11
Properties
(calculated by RDKit )
Molecular Weight
389.06
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
2.65
TPSA
88.16
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.66
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Histone Acetyltransferase
KAT6A
KAT6A inhibitor
KAT6A, KAT6B
Primary Target
Histone Acetyltransferases
MOA
Inhibitor
Member status
member
Targeted domain
AcCoA binding site
Control
Compound 187Compound 188Compound 189
Pathway
Epigenetics
Chromatin/Epigenetic
Control name
WM-2474
Target subclass
Lysine Acetyltransferase
Recommended Cell Concentration
1 uM
Source data